Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Akeso Biopharma

Biotech & Life Sciences · Zhongshan, China · Founded 2012 · IPO 2020 Decacorn

A clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies

Valuation
$14B
Market cap · May/2026
Revenue
$292M
Latest reported FY

Investors

4 investors on Akeso Biopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage
Loyal Valley Capital
ShenZhen GTJA Investment Group
Sino Biopharmaceutical
Ally Bridge Group

Global footprint

Where Akeso Biopharma has talent and traffic

AI talent share
0.9% of workforce is AI talent
(1 of 112 staff)
Core AI00%
Other AI10.89%
Non-AI workforce11199.11%
Workforce by country
🇨🇳 China · Zhongshan HQ
Book a demo for the full country breakdown
Web traffic by country
27K monthly visits
across markets
🇺🇸 United States42.2%
🇨🇳 China38.9%
🇭🇰 Hong Kong7.4%
🇬🇧 United Kingdom4.8%
🇮🇳 India3.7%
Top 5 markets shown

Patent intelligence

$59M patent portfolio · 102 active families

Estimated portfolio value
$59M
0.41% of market cap · 13.1× smaller than top peer BioNTech ($780M)
102 active patent families
Where Akeso Biopharma innovates Molecular biologyPharmaceutical drugAntiendomysial antibodiesHeavy chainAcid amino sequences

Where Akeso Biopharma concentrates vs peers

Each axis is a top-10 topic across Akeso Biopharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Akeso Biopharma's 1 investments and acquisitions.

Every disclosed deal where Akeso Biopharma appeared as a backer or acquirer, 2025–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

1 deals across Akeso Biopharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Akeso Biopharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Akeso Biopharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        1 of 1 deals

        Market sentiment

        What the market is saying about Akeso Biopharma

        An AI-synthesized read of the highest-engagement posts about Akeso Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Akeso Biopharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.